Literature DB >> 10660529

Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin.

P R Dash1, M L Read, K D Fisher, K A Howard, M Wolfert, D Oupicky, V Subr, J Strohalm, K Ulbrich, L W Seymour.   

Abstract

Binding of serum proteins to polyelectrolyte gene delivery complexes is thought to be an important factor limiting bloodstream circulation and restricting access to target tissues. Protein binding can also inhibit transfection activity in vitro. In this study a multivalent reactive hydrophilic polymer has been used to inhibit protein binding. This polymer is based on poly-[N-(2-hydroxypropyl)methacrylamide] (pHPMA) bearing pendent oligopeptide (Gly-Phe-Leu-Gly) side chains terminated in reactive 4-nitrophenoxy groups (8.6 mol%). The polymer reacts with the primary amino groups of poly(L-lysine) (pLL) and produces a hydrophilic coating on the surface of pLL.DNA complexes (as measured by fluorescamine). The resulting pHPMA-coated complexes show a decreased surface charge (from +14 mV for pLL.DNA complexes to -25 mV for pHPMA-modified complexes) as measured by zeta potential analysis. The pHPMA-coated complexes also show a slightly increased average diameter (approximately 90 nm compared with 60 nm for pLL. DNA complexes) as viewed by atomic force and transmission electron microscopy and around 100 nm as viewed by photon correlation spectroscopy. They are completely resistant to protein interaction, as determined by turbidometry and SDS-polyacrylamide gel electrophoresis analysis of complexes isolated from plasma, and show significantly decreased nonspecific uptake into cells in vitro. Spare reactive ester groups can be used to conjugate targeting ligands (e.g. transferrin) on to the surface of the complex to provide a means of tissue-specific targeting and transfection. The properties of these complexes therefore make them promising candidates for targeted gene delivery, both in vitro and potentially in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10660529     DOI: 10.1074/jbc.275.6.3793

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

Review 1.  Nanotherapeutic approaches for the treatment of rheumatoid arthritis.

Authors:  Christine T N Pham
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-11

2.  String-like micellar nanoparticles formed by complexation of PEG-b-PPA and plasmid DNA and their transfection efficiency.

Authors:  Xuan Jiang; Derek Leong; Yong Ren; Zhiping Li; Michael S Torbenson; Hai-Quan Mao
Journal:  Pharm Res       Date:  2011-04-16       Impact factor: 4.200

3.  The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

Authors:  Shan Gao; Frederik Dagnaes-Hansen; Ebbe Juel Bech Nielsen; Jesper Wengel; Flemming Besenbacher; Kenneth Alan Howard; Jørgen Kjems
Journal:  Mol Ther       Date:  2009-04-28       Impact factor: 11.454

4.  Diseases originate and terminate by genes: unraveling nonviral gene delivery.

Authors:  Rajan Swami; Indu Singh; Wahid Khan; Sistla Ramakrishna
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

5.  PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting.

Authors:  Tae Hyung Kim; Young Gi Jo; Hai Hua Jiang; Sung Mook Lim; Yu Seok Youn; Seulki Lee; Xiaoyuan Chen; Youngro Byun; Kang Choon Lee
Journal:  J Control Release       Date:  2012-07-21       Impact factor: 9.776

6.  Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Xu Wang; Jonathan E Zuckerman; Chung Hang J Choi; Bingsen Zhou; Dongsheng Wang; Sreenivas Nannapaneni; Lydia Koenig; Zhengjia Chen; Zhuo Georgia Chen; Yun Yen; Mark E Davis; Dong M Shin
Journal:  J Control Release       Date:  2012-02-08       Impact factor: 9.776

Review 7.  RNAi therapeutic strategies for acute respiratory distress syndrome.

Authors:  Melissa L Jagrosse; David A Dean; Arshad Rahman; Bradley L Nilsson
Journal:  Transl Res       Date:  2019-07-27       Impact factor: 7.012

8.  Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model.

Authors:  Kenneth A Howard; Søren R Paludan; Mark A Behlke; Flemming Besenbacher; Bent Deleuran; Jørgen Kjems
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

9.  Stabilized nonviral formulations for the delivery of MCP-1 gene into cells of the vasculoendothelial system.

Authors:  Martin C Lenter; Patrick Garidel; Jaroslav Pelisek; Ernst Wagner; Manfred Ogris
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

10.  Cyclic RGD-targeting of reversibly stabilized DNA nanoparticles enhances cell uptake and transfection in vitro.

Authors:  Qing-Hui Zhou; Ye-Zi You; Chao Wu; Yi Huang; David Oupický
Journal:  J Drug Target       Date:  2009-06       Impact factor: 5.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.